<DOC>
	<DOCNO>NCT02021929</DOCNO>
	<brief_summary>The main purpose clinical trial determine safety effect study drug , sorafenib , adult diagnose hepatopulmonary syndrome ( HPS ) . The study evaluate well drug tolerate effect level oxygen blood function lung vessel .</brief_summary>
	<brief_title>Sorafenib Hepatopulmonary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hepatopulmonary Syndrome</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Diagnosis HPS : 1 . AaPO2 ≥ 15 mm Hg ( ≥ 20 mm Hg age &gt; 64 yr ) 2 . Intrapulmonary shunt 3 . Absence significant restriction ( TLC &lt; 70 % ) obstruction ( FEV1 &lt; 80 % &amp; FEV1/FVC &lt; 70 % ) 4 . Presence cirrhosis/hepatic fibrosis and/or portal hypertension ChildPugh class A B liver disease Platelet count ≥ 30 ×10e9 per liter Hemoglobin ≥ 8.5 g per deciliter International normalize ratio ≤ 2.3 Albumin ≥ 2.8 g per deciliter Total bilirubin ≤ 5 mg per deciliter Alanine aminotransferase aspartate aminotransferase ≤ 5 time upper limit normal range Serum creatinine ≤ 1.5 time upper limit normal range receive dialysis Negative pregnancy test ( woman childbearing potential ) screen baseline visit . Postmenopausal woman ( defined menses one year ) surgically sterilize woman require undergo pregnancy test . Subjects ( men woman ) childbearing potential must agree use medically acceptable contraception begin sign Informed Consent Form least 14 day last dose study drug . Age ≥ 21 year Ability provide inform consent Recent chronic heavy alcohol consumption Enrollment clinical trial concurrent use another investigational drug device therapy ( i.e. , outside study treatment ) , within 28 day screen visit Current hepatic encephalopathy Active infection Diagnosis portopulmonary hypertension WHO Class IV functional status Congenital longQT syndrome Subjects use strong CYP3A4 inducer ( e.g. , phenytoin , carbamazepine , phenobarbital , St. John 's Wort [ Hypericum perforatum ] , dexamethasone dose great 16 mg daily , rifampin [ rifampicin ] , and/or rifabutin ) within 28 day randomization Subjects currently take Coumadin® ( warfarin ) Active clinically significant cardiac disease , include : 1 . Active coronary artery disease 2 . Unstable angina ( anginal symptom rest ) , newonset angina within 12 week randomization , myocardial infarction within 24 week randomization Liver solid organ transplant recipient Expectation liver transplant within four month randomization Hepatocellular carcinoma meet follow criterion : 1 . Single lesion ≤ 3 cm document LIRADS criterion 2 . Complete response ablative therapy ( TACE , RFA , alcohol ablation ) use modify RECIST criterion one month therapy two treatment 3 . No lesion develop initiation HCC therapy Uncontrolled hypertension ( systolic pressure &gt; 140 mm Hg diastolic pressure &gt; 90 mm Hg repeat measurement ) despite optimal medical management . Any hemorrhage/bleeding event NCICommon Toxicity Criteria Adverse Effects v4.0 Grade 3 high within 4 week randomization Presence nonhealing wound , nonhealing ulcer , bone fracture Women pregnant breastfeed Major surgery 28 day prior randomization Subjects previously untreated concurrent cancer except cervical cancer insitu , treat basal cell carcinoma , superficial bladder tumor . Subjects survive cancer curatively treat without evidence disease 3 year randomization allow . All cancer treatment ( chemotherapy , radiation therapy , surgery , immunotherapy , biologic therapy , tumor embolization ) must complete least 3 year prior study entry ( i.e. , signature date inform consent form ) . Inability comply protocol and/or willing available followup assessment</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Randomized Controlled Trial</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>sorafenib</keyword>
	<keyword>Hepatopulmonary Syndrome</keyword>
</DOC>